This filing is purely administrative with no trading implications. Monitor for any future capital increases or warrant exercises, but the current filing does not alter the company's financial outlook or operations.
GMAB drugs
GMAB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $24.58entry
- T+1 · 5mo ago +0.65%α +1.25% · $24.74
- T+5 · 5mo ago +4.19%α +5.57% · $25.61
- T+20 · 4mo ago +17.17%α +17.92% · $28.80
- T+60 · 2mo ago +34.42%α +33.42% · $33.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Genmab A/S filed its updated Articles of Association via a 6-K on June 15, 2026, reflecting standard corporate governance provisions including share capital details, authorized capital increases, employee warrant programs, and a board indemnification scheme. This is a routine administrative filing with no financial results, material events, or strategic announcements.
Key Facts
- Share capital is DKK 62,353,067 divided into shares of DKK 1 each.
- Board authorized until March 12, 2029 to increase share capital by up to DKK 6,600,000 (with or without pre-emption rights).
- Multiple warrant programs for employees (excluding executive management) with up to DKK 750,000 nominal each, expiring between 2026 and 2030.
- Board authorized to issue convertible debt instruments up to DKK 3,000,000 nominal until March 12, 2029.
- Indemnification scheme for board members established through March 12, 2029.
Financial Impact
No material financial impact; routine governance update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000090 |
| Document: gmab_20260615xx6k.htm | 0001434265-26-000090 |
| Document: 0001434265-26-000090-index-headers.html | 0001434265-26-000090 |
| Document: 0001434265-26-000090-index.html | 0001434265-26-000090 |
| Document: 0001434265-26-000090.txt | 0001434265-26-000090 |
Track record
31 reports on GMAB
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers